Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
stocks
Vegemite owner’s shares remain expensive on normalising profits.
stocks
Ask the analyst: Where does GYG stand following its US exit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,479.87 | 28.20 | -0.33% |
| DAX 40 | 25,817.89 | 38.58 | 0.15% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,651.77 | 27.26 | -0.26% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,811.24 | 48.14 | 0.35% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |